Addition of hrsACE2, however, again reduced SARS-CoV-2 levels in a dose-dependent manner. “Our findings not only suggest that tissue organoids can be used to study the effects of SARS-CoV-2 on extrapulmonary tissues, but also suggest that rhsACE2 might block the virus from entering target cells,” says Penninger.